Ask AI
ProCE Banner Activity

FAQs: Management of HER2-Altered Advanced NSCLC

Clinical Thought

In this commentary, experts address questions about the selection and sequencing of available HER2-directed agents in the management of patients with advanced NSCLC harboring HER2 alterations, including how to proactively manage some adverse events of special interest.

Released: April 06, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, nurses, and other HCPs who care for patients with NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate the latest clinical data and guidelines for treating HER2-mutant and overexpressing NSCLC, including emerging data for the use of HER2-directed ADCs in earlier lines of therapy

  • Implement personalized care plans for patients with NSCLC, including the use of reduced dosing regimens to mitigate and manage treatment-related adverse events in patients receiving HER2-directed ADC therapy

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS, FASCO: consultant/advisor/speaker: AstraZeneca, Bicycle, Bristol Myers Squibb, Cardinal Health, Catalyst, Foresight, Genentech/Roche, Johnson & Johnson, Natera, Nuvalent, OncoHost, Regeneron; researcher (paid to institution): Amgen, Johnson & Johnson, Merck, Trizell.

Estelamari Rodriguez, MD, MPH: consultant/advisor/speaker: Amgen, AstraZeneca, Daiichi Sankyo, Genentech, Janssen, Nuvalent, NuvationBio. Pfizer, Regeneron.